頸動脈狭窄治療法の世界市場予測・分析2019-2023

◆英語タイトル:Carotid Artery Stenosis Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR32088
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年9月28日
◆ページ数:152
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、頸動脈狭窄治療法の世界市場について調べ、頸動脈狭窄治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、頸動脈狭窄治療法の市場規模をセグメンテーション別(製品別(抗血栓薬、抗高脂血症薬、降圧薬)、)と地域別(グローバル)に分けて算出しました。Technavio社は頸動脈狭窄治療法の世界市場規模が2019-2023期間中に年平均4%成長すると予測しています。
・サマリー
・レポートの範囲
・頸動脈狭窄治療法の市場状況
・頸動脈狭窄治療法の市場規模
・頸動脈狭窄治療法の市場予測
・頸動脈狭窄治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(抗血栓薬、抗高脂血症薬、降圧薬)
・頸動脈狭窄治療法の顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Carotid Artery Stenosis Therapeutics Market: About this market

Technavio’s carotid artery stenosis therapeutics market analysis considers sales from antithrombotics, antihyperlipidemic, and antihypertensives products. Our analysis also considers the sales of carotid artery stenosis therapeutics in Asia, Europe, North America, and ROW. In 2018, the antithrombotics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the use of antithrombotics as the first-line treatment option for carotid artery stenosis will play a significant role in the antithrombotics segment to maintain its market position. Also, our global carotid artery stenosis therapeutics market report looks at factors such as the increasing risk factors for carotid artery stenosis, increasing geriatric population, and growing awareness about carotid artery stenosis. However, the availability of substitutes, delay in diagnosis, and stringent regulations may hamper the growth of the carotid artery stenosis therapeutics industry over the forecast period.

Global Carotid Artery Stenosis Therapeutics Market: Overview

Growing awareness about carotid artery stenosis

The growing awareness about carotid artery stenosis is important for its prevention, as delay in the diagnosis of this disease can be life-threatening. Several awareness campaigns are being conducted globally for carotid artery stenosis that includes hemorrhagic strokes, ischemic strokes, and transient ischemic attacks. The demand for carotid artery stenosis therapeutics is increasing with the growing awareness about stroke management and carotid artery stenosis through multiple educational programs initiated by government organizations. For instance, May is observed as the National Stroke Awareness Month by the Division for Heart Disease and Stroke Prevention (DHDSP). Similarly, the Stroke Awareness Foundation promotes awareness among communities and families about the devastating effects of strokes and carotid artery stenosis. Such awareness programs lead to the expansion of the global carotid artery stenosis therapeutics market at a CAGR of over 4% during the forecast period.

Increasing demand for curative therapies

The lack of approved drugs, coupled with a high prevalence of carotid artery stenosis has driven the need for effective curative therapies. Also, the consumption of off-label drugs cause side-effects which is further increasing the demand for new curative therapies. Most patients are opting for alternative options such as stents, angioplasty, and carotid endarterectomy for the treatment of carotid artery stenosis. These developments are expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global carotid artery stenosis therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global carotid artery stenosis therapeutics market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading carotid artery stenosis therapeutics manufacturers, that include Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi.

Also, the carotid artery stenosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Antithrombotics – Market size and forecast 2018-2023

Antihyperlipidemics – Market size and forecast 2018-2023

Antihypertensives – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Entry of generic drugs

Technological advances in medical devices

Increasing demand for curative therapies

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Amgen Inc.

AstraZeneca Plc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co.

Eli Lilly and Co.

F. Hoffmann-La Roche Ltd.

Johnson & Johnson Services Inc.

Merck & Co., Inc.

Pfizer Inc.

Sanofi

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Product – Market share 2018-2023 (%)

Exhibit 19: Comparison by product

Exhibit 20: Antithrombotics – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Antithrombotics – Year-over-year growth 2019-2023 (%)

Exhibit 22: Antihyperlipidemics – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Antihyperlipidemics – Year-over-year growth 2019-2023 (%)

Exhibit 24: Antihypertensives – Market size and forecast 2018-2023 ($ millions)

Exhibit 25: Antihypertensives – Year-over-year growth 2019-2023 (%)

Exhibit 26: Market opportunity by product

Exhibit 27: Customer landscape

Exhibit 28: Market share by geography 2018-2023 (%)

Exhibit 29: Geographic comparison

Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: North America – Year-over-year growth 2019-2023 (%)

Exhibit 32: Top 3 countries in North America

Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in Europe

Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in Asia

Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 41: Top 3 countries in ROW

Exhibit 42: Key leading countries

Exhibit 43: Market opportunity

Exhibit 44: Impact of drivers and challenges

Exhibit 45: Vendor landscape

Exhibit 46: Landscape disruption

Exhibit 47: Vendors covered

Exhibit 48: Vendor classification

Exhibit 49: Market positioning of vendors

Exhibit 50: Amgen Inc. – Vendor overview

Exhibit 51: Amgen Inc. – Business segments

Exhibit 52: Amgen Inc. – Organizational developments

Exhibit 53: Amgen Inc. – Geographic focus

Exhibit 54: Amgen Inc. – Key offerings

Exhibit 55: Amgen Inc. – Key customer

Exhibit 56: AstraZeneca Plc – Vendor overview

Exhibit 57: AstraZeneca Plc – Business segments

Exhibit 58: AstraZeneca Plc – Organizational developments

Exhibit 59: AstraZeneca Plc – Geographic focus

Exhibit 60: AstraZeneca Plc – Key offerings

Exhibit 61: AstraZeneca Plc – Key customers

Exhibit 62: Boehringer Ingelheim International GmbH – Vendor overview

Exhibit 63: Boehringer Ingelheim International GmbH – Business segments

Exhibit 64: Boehringer Ingelheim International GmbH – Organizational developments

Exhibit 65: Boehringer Ingelheim International GmbH – Geographic focus

Exhibit 66: Boehringer Ingelheim International GmbH – Segment focus

Exhibit 67: Boehringer Ingelheim International GmbH – Key offerings

Exhibit 68: Boehringer Ingelheim International GmbH – Key customers

Exhibit 69: Bristol-Myers Squibb Co. – Vendor overview

Exhibit 70: Bristol-Myers Squibb Co. – Business segments

Exhibit 71: Bristol-Myers Squibb Co. – Organizational developments

Exhibit 72: Bristol-Myers Squibb Co. – Geographic focus

Exhibit 73: Bristol-Myers Squibb Co. – Key offerings

Exhibit 74: Bristol-Myers Squibb Co. – Key customers

Exhibit 75: Eli Lilly and Co. – Vendor overview

Exhibit 76: Eli Lilly and Co. – Business segments

Exhibit 77: Eli Lilly and Co. – Organizational developments

Exhibit 78: Eli Lilly and Co. – Geographic focus

Exhibit 79: Eli Lilly and Co. – Segment focus

Exhibit 80: Eli Lilly and Co. – Key offerings

Exhibit 81: Eli Lilly and Co. – Key customers

Exhibit 82: F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 83: F. Hoffmann-La Roche Ltd. – Business segments

Exhibit 84: F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 85: F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 86: F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 87: F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 88: F. Hoffmann-La Roche Ltd. – Key customers

Exhibit 89: Johnson & Johnson Services, Inc. – Vendor overview

Exhibit 90: Johnson & Johnson Services, Inc. – Business segments

Exhibit 91: Johnson & Johnson Services, Inc. – Organizational developments

Exhibit 92: Johnson & Johnson Services, Inc. – Geographic focus

Exhibit 93: Johnson & Johnson Services, Inc. – Segment focus

Exhibit 94: Johnson & Johnson Services, Inc. – Key offerings

Exhibit 95: Johnson & Johnson Services, Inc. – Key customers

Exhibit 96: Merck & Co. Inc. – Vendor overview

Exhibit 97: Merck & Co. Inc. – Business segments

Exhibit 98: Merck & Co. Inc. – Organizational developments

Exhibit 99: Merck & Co. Inc. – Geographic focus

Exhibit 100: Merck & Co. Inc. – Segment focus

Exhibit 101: Merck & Co. Inc. – Key offerings

Exhibit 102: Merck & Co. Inc. – Key customers

Exhibit 103: Pfizer Inc. – Vendor overview

Exhibit 104: Pfizer Inc. – Business segments

Exhibit 105: Pfizer Inc. – Organizational developments

Exhibit 106: Pfizer Inc. – Geographic focus

Exhibit 107: Pfizer Inc. – Segment focus

Exhibit 108: Pfizer Inc. – Key offerings

Exhibit 109: Pfizer Inc. – Key customers

Exhibit 110: Sanofi – Vendor overview

Exhibit 111: Sanofi – Business segments

Exhibit 112: Sanofi – Organizational developments

Exhibit 113: Sanofi – Geographic focus

Exhibit 114: Sanofi – Segment focus

Exhibit 115: Sanofi – Key offerings

Exhibit 116: Sanofi – Key customers

Exhibit 117: Validation techniques employed for market sizing

Exhibit 118: Definition of market positioning of vendors



【掲載企業】

Amgen Inc.
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co.
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services Inc.
Merck & Co., Inc.
Pfizer Inc.
Sanofi

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[頸動脈狭窄治療法の世界市場予測・分析2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆